Claims for Patent: 8,328,876

Summary for Patent: 8,328,876

Title:	Bone matrix compositions and methods
Abstract:	The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and/or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. Ona assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and/or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and/or chondrogenic activity of human DBM when tested using this assay system.
Inventor(s):	Behnam; Keyvan (Redbank, NJ), Cioffi; Christopher (North Brunswick, NJ)
Assignee:	Warsaw Orthopedic, Inc. (Warsaw, IN)
Application Number:	10/584,981
Patent Claims:	1. A modified bone matrix comprising a bone matrix that has been exposed to collagenase to produce a modified bono matrix, wherein the level of at least one biological activity of the modified bone matrix is increased relative to its level in an unmodified control bone matrix, and wherein the at least one biological activity is selected from the group consisting of osteoinductive activity, osteogenic activity, and chondrogenic activity. 2. The modified bone matrix of claim 1, wherein the biological activity is osteoinductive activity. 3. The modified bone matrix of claim 1, wherein the biological activity is osteogenic activity. 4. The modified bone matrix of claim 3, wherein a digestion is performed at about 37 degrees Celsius. 5. The modified bone matrix of claim 1, wherein the biological activity is chondrogenic activity. 6. The modified bone matrix of claim 1, wherein the bone matrix is demineralized bone matrix derived at least in part from human bone. 7. The modified bone matrix of claim 1, wherein the bone matrix comprises mineralized bone matrix, partially demineralized bone matrix, demineralized bone matrix, deorganified bone matrix, anorganic matrix, or a mixture thereof. 8. The modified bone matrix of claim 1, wherein the bone matrix comprises a mineralized, partially demineralized, demineralized, deorganified, or anorganic bone section. 9. The modified bone matrix of claim 1, wherein undifferentiated mesenchymal cells treated with the modified bone matrix display increased expression of a marker indicative of osteoblastic or chondrocytic differentiation relative to cells treated with the unmodified control bone matrix. 10. The modified bone matrix of claim 9, wherein the marker is alkaline phosphatase. 11. The modified bone matrix of claim 9, wherein expression of the marker is within a factor of 2 relative to that induced by treating the undifferentiated cells with BMP-2. 12. The modified bone matrix of claim 9, wherein expression of the marker is increased by a factor of approximately 200-450 relative to expression induced by treating the undifferentiated cells with 10% fetal bovine serum. 13. The modified bone matrix of claim 9, wherein expression of the marker is increased by a factor of between approximately 20-900 relative to expression induced by treating the undifferentiated cells with an inactivated bone matrix. 14. The modified bone matrix of claim 1, wherein solubility of the modified bone matrix is greater than solubility of the unmodified bone matrix. 15. The modified bone matrix of claim 1, wherein one or more integrin binding sites is modified relative to an integrin binding site in a control bone matrix. 16. The modified bone matrix of claim 1, wherein the modified bone matrix has osteoinductive activity in an animal species in which the unmodified bone matrix is not osteoinductive. 17. The modified bone matrix of claim 16, wherein the species is selected from the group consisting of: dog, squirrel monkey, and human. 18. The modified bone matrix of claim 1, further comprising one or more bioactive agents selected from the group consisting of: small molecules, chemical compounds, cells, polynucleotides, proteins, protein fragments, peptides, drugs, viruses, antibiotics, anti-neoplastic agents, growth factors, hematopoietic factors, hormones, wound healing factors, and nutrients. 19. The modified bone matrix of claim 1 further comprising an agent selected from the group consisting of: carriers, stabilizing agents, diffusion barrier agents, and water reducing agents. 20. A device for bone repair comprising the modified bone matrix of claim 1, optionally including one or more additional components, formed into a device having a shape suitable for implantation into a subject. 21. A method of treating a subject comprising the step of: implanting the modified bone matrix of claim 1 into a subject at a site of a bone or cartilage defect. 22. A method of preparing a cell composition for implantation into a subject comprising steps of: obtaining a cell from a subject; culturing the cell in vitro; contacting the cell with the modified bone matrix of claim 1.

Details for Patent 8,328,876

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2023-12-31